# To Demonstrate the Relative Bioavailability of Alprazolam Tablets, 1 mg

> **NCT00913341** · PHASE1 · COMPLETED · sponsor: **Sandoz** · enrollment: 30 (actual)

## Conditions studied

- Anxiety

## Interventions

- **DRUG:** Alprazolam Tablets, 1 mg (Geneva Pharmaceuticals)
- **DRUG:** Alprazolam Tablets, 1 mg (The Upjohn Company)

## Key facts

- **NCT ID:** NCT00913341
- **Lead sponsor:** Sandoz
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1991-11
- **Primary completion:** 1991-11
- **Final completion:** 1991-11
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2017-03-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00913341

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00913341, "To Demonstrate the Relative Bioavailability of Alprazolam Tablets, 1 mg". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00913341. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*